{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["Colorectal Carcinoma","Carcinoma","Colon cancer","Colorectal Neoplasms","Vaccinia"],"disease":["Colorectal Carcinoma","Carcinoma","Colon Cancer","Colorectal Neoplasms","Vaccinia"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2104857"],"location":["Canada"],"study_start_month":["10"],"keyword":["Molgramostim","JX-594","Pexa-vec","Sargramostim","Liver metastasis","Metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors","description":"This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.","dates":{"creation":"2011-10-15"},"accession":"2104857","cross_references":{"ClinicalTrials___gov":["NCT01329809"]}}